Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
作者： Dorothee Foernzler , Friedemann Krause , Paul Delmar , Stefan Scherer
DOI:
关键词:
摘要: The present invention provides methods for improving the treatment effect of a chemotherapy regimen patient suffering from pancreatic cancer, in particular metastatic cancer by adding bevacizumab (Avastin®) to determining expression level, blood plasma one or more VEGFA, VEGFR2 and PLGF relative control levels patients diagnosed with cancer. In particular, effect, wherein is overall survival and/or progression-free patient. further assessing sensitivity responsiveness combination regimen,
lens.org参考文章(64)
Napoleone Ferrara, Brandon Willis, Ellen Filvaroff, Diagnostics and treatments for vegf-independent tumors ,(2009)
Maximiliano Vasquez, Charles Theuer, Humanized Endoglin Antibodies ,(2009)
JGR Hurrell (Ed), Monoclonal Hybridoma Antibodies: Techniques and Applications ,(1982)
Robert Tibshirani, Trevor Hastie, Jerome H. Friedman, The Elements of Statistical Learning ,(2001)
David G. Stork, Richard O. Duda, Peter E. Hart, Pattern Classification (2nd Edition) Wiley-Interscience. ,(2000)
Federica Sotgia, Michael P. Lisanti, Richard G. Pestell, A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm ,(2010)
George D. Yancopoulos, John S. Rudge, Yuping Xia, Method of using a variant of vegf receptor to treat psoriasis and to enhance wound healing ,(2002)
Margaret Sullivan Pepe, The Statistical Evaluation of Medical Tests for Classification and Prediction ,(2003)
Nina Korsisaari, Robert D. Mass, Napoleone Ferrara, Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors ,(2007)
Ralph Markus Wirtz, Christine Schröder, Karin Milde-Langosch, Maike Ihnen, The present invention relates to methods for prediction of the therapeutic success of breast cancer therapy ,(2008)